

Introducing

PrOctreotide for Injectable Suspension

First generic alternative to PrSandostatin LAR®







Strength	Size	DIN	UPC	Code	Imperial AB	Imperial BC	K&F	McKesson	NuQuest
10 mg	1	02503751	068510998460	65409- 0001	935973	998460	164962	166394	OCTR010TEV
20 mg	1	02503778	068510998477	65410- 0001	936013	993778	164963	166395	OCTR020TEV
30 mg	1	02503786	068510998484	65411- 0001	936039	998484	164964	166396	OCTR030TEV

- > Therapeutic Class Synthetic Octapeptide Analogue of Somatostatin
- > Market Value \$80.4M*

^{*}Source: IQVIA, CD&H Audit, MAT June 2021.

Octreotide Patient Care ProgramSM

Program at a glance



Patient enrolment

Enroling in the Octreotide Patient Care ProgramSM is fast and easy!

The patient, their prescriber or a member of their pharmacy team can quickly get patients the support they need by sending the enrolment form by fax to 1.833.377.0557 or email to OctreotidePatientCare@teva-canada.com

All program resources can be accessed at: TevaCanada.com/Octreotide-Support



Financial support

Trained case managers will help provide reimbursement navigation and co-pay support.



Injection Administration

Injections will be administered by a nurse, and patients will be given the option of having injection administration scheduled either at home or in a clinic setting.

PrOctreotide for Injectable Suspension therapy must be administered by a trained healthcare professional only.

Call 1.877.445.6984

TevaCanada.com/Octreotide-Support

Contact one of our trained case managers today!

Octreotide Patient Care ProgramSM

Phone: 1.877.445.6984 Fax: 1.833.377.0557

Email: OctreotidePatientCare@teva-canada.com

(Monday to Friday, 8 am to 8 pm ET)



Patient Support Program